Literature DB >> 21317995

Treatment of alcoholic liver disease.

Thomas H Frazier1, Abigail M Stocker, Nicole A Kershner, Luis S Marsano, Craig J McClain.   

Abstract

Alcoholic liver disease (ALD) remains a major cause of liver-related mortality in the US and worldwide. The correct diagnosis of ALD can usually be made on a clinical basis in conjunction with blood tests, and a liver biopsy is not usually required. Abstinence is the hallmark of therapy for ALD, and nutritional therapy is the first line of therapeutic intervention. The role of steroids in patients with moderate to severe alcoholic hepatitis is gaining increasing acceptance, with the caveat that patients be evaluated for the effectiveness of therapy at 1 week. Pentoxifylline appears to be especially effective in ALD patients with renal dysfunction/hepatorenal syndrome. Biologics such as specific anti-TNFs have been disappointing and should probably not be used outside of the clinical trial setting. Transplantation is effective in patients with end-stage ALD who have stopped drinking (usually for ≥6 months), and both long-term graft and patient survival are excellent.

Entities:  

Keywords:  alcoholic liver disease; cytokines; diagnosis; nutrition; steroids; transplantation; treatment

Year:  2011        PMID: 21317995      PMCID: PMC3036962          DOI: 10.1177/1756283X10378925

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  163 in total

1.  Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers.

Authors:  Johanna Hietala; Heidi Koivisto; Petra Anttila; Onni Niemelä
Journal:  Alcohol Alcohol       Date:  2006-06-23       Impact factor: 2.826

Review 2.  Alcoholic liver disease.

Authors:  Robert S O'Shea; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 3.  Alcoholic hepatitis.

Authors:  Michael R Lucey; Philippe Mathurin; Timothy R Morgan
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

4.  Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study.

Authors:  M I Lucena; R J Andrade; J P de la Cruz; M Rodriguez-Mendizabal; E Blanco; F Sánchez de la Cuesta
Journal:  Int J Clin Pharmacol Ther       Date:  2002-01       Impact factor: 1.366

5.  Outcomes of residential treatment of substance abuse in hospital- and community-based programs.

Authors:  R H Moos; M J King; M A Patterson
Journal:  Psychiatr Serv       Date:  1996-01       Impact factor: 3.084

6.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

Authors:  E Akriviadis; R Botla; W Briggs; S Han; T Reynolds; O Shakil
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

7.  Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis.

Authors:  B Fromenty; S Grimbert; A Mansouri; M Beaugrand; S Erlinger; A Rötig; D Pessayre
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

8.  Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis.

Authors:  S Hirsch; D Bunout; P de la Maza; H Iturriaga; M Petermann; G Icazar; V Gattas; G Ugarte
Journal:  JPEN J Parenter Enteral Nutr       Date:  1993 Mar-Apr       Impact factor: 4.016

9.  Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study.

Authors:  Maurizio Biselli; Annagiulia Gramenzi; Massimo Del Gaudio; Matteo Ravaioli; Giovanni Vitale; Stefano Gitto; Gian Luca Grazi; Antonio Daniele Pinna; Pietro Andreone; Mauro Bernardi
Journal:  J Clin Gastroenterol       Date:  2010-01       Impact factor: 3.062

10.  S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model.

Authors:  Amel Karaa; Kyle J Thompson; Iain H McKillop; Mark G Clemens; Laura W Schrum
Journal:  Shock       Date:  2008-08       Impact factor: 3.454

View more
  45 in total

1.  Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury.

Authors:  Aditya Ambade; Donna Catalano; Arlene Lim; Andre Kopoyan; Scott A Shaffer; Pranoti Mandrekar
Journal:  J Hepatol       Date:  2014-05-22       Impact factor: 25.083

Review 2.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  P2X7 receptor-targeted regulation by tetrahydroxystilbene glucoside in alcoholic hepatosteatosis: A new strategy towards macrophage-hepatocyte crosstalk.

Authors:  Yu Zhang; Min Jiang; Ben-Wen Cui; Cheng Hua Jin; Yan-Ling Wu; Yue Shang; Hong-Xu Yang; Mei Wu; Jian Liu; Chun-Ying Qiao; Zi-Ying Zhan; Huan Ye; Guang-Hao Zheng; Quan Jin; Li-Hua Lian; Ji-Xing Nan
Journal:  Br J Pharmacol       Date:  2020-02-23       Impact factor: 8.739

Review 4.  New paradigms in management of alcoholic hepatitis: a review.

Authors:  Sandeep Singh Sidhu; Omesh Goyal; Harsh Kishore; Simran Sidhu
Journal:  Hepatol Int       Date:  2017-02-28       Impact factor: 6.047

Review 5.  Alcohol abuse: critical pathophysiological processes and contribution to disease burden.

Authors:  Patricia E Molina; Jason D Gardner; Flavia M Souza-Smith; Annie M Whitaker
Journal:  Physiology (Bethesda)       Date:  2014-05

6.  Alcohol-induced miR-155 and HDAC11 inhibit negative regulators of the TLR4 pathway and lead to increased LPS responsiveness of Kupffer cells in alcoholic liver disease.

Authors:  Shashi Bala; Timea Csak; Karen Kodys; Donna Catalano; Aditya Ambade; Istvan Furi; Patrick Lowe; Yeonhee Cho; Arvin Iracheta-Vellve; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2017-06-05       Impact factor: 4.962

7.  Regulatory T cells suppress excessive lipid accumulation in alcoholic liver disease.

Authors:  Hongwu Wang; Ting Wu; Yaqi Wang; Xiaoyang Wan; Junying Qi; Lan Li; Xiaojing Wang; Xiaoping Luo; Qin Ning
Journal:  J Lipid Res       Date:  2019-02-21       Impact factor: 5.922

8.  Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.

Authors:  Aditya Ambade; Patrick Lowe; Karen Kodys; Donna Catalano; Benedek Gyongyosi; Yeonhee Cho; Arvin Iracheta-Vellve; Adeyinka Adejumo; Banishree Saha; Charles Calenda; Jeeval Mehta; Eric Lefebvre; Pamela Vig; Gyongyi Szabo
Journal:  Hepatology       Date:  2019-02-12       Impact factor: 17.425

Review 9.  Focus on alcoholic liver disease: from nosography to treatment.

Authors:  Letiția Adela Maria Streba; Cristin Constantin Vere; Costin Teodor Streba; Marius Eugen Ciurea
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

10.  Activation of RhoA in alcohol-induced intestinal barrier dysfunction.

Authors:  Jing Tong; Ying Wang; Bing Chang; Dai Zhang; Pengliang Liu; Bingyuan Wang
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.